The FDA is expected to decide on treatments for COPD, psoriasis, rare neuroendocrine tumors, and a next-generation COVID-19 vaccine.

Among patients with previous sinus surgery for chronic rhinosinusitis with nasal polyps, the number of past surgeries did not ...

The European Medicines Agency (EMA) has agreed to review GSK’s application of expanding Nucala’s (mepolizumab) use as add-on ...

The active ingredient in Nucala is mepolizumab. (An active ingredient is what makes a drug work.) Nucala is given as an injection under your skin. A healthcare professional may give you these ...

GlaxoSmithKline’s Nucala (mepolizumab) has gained a new FDA approval for the rare autoimmune disease eosinophilic granulomatosis with polyangiitis (EGPA). Nucala, an interleukin-5 (IL-5 ...

EMA accepts for review GSK’s application to expand use of Nucala for COPD treatment: London, UK Wednesday, March 26, 2025, 11:00 Hrs [IST] GSK plc announced that the European Me ...

Researchers assessed patients receiving omalizumab, dupilumab, mepolizumab, benralizumab, reslizumab or tezepelumab for asthma. Adherence was deemed intermittent based on heatmaps. SAN DIEGO ...

GSK plc (LSE/NYSE: GSK) today announced that the European Medicines Agency (EMA) has accepted for review its application to expand the use of Nucala (mepolizumab), a monoclonal antibody that targets ...

GSK said on Monday that the European Medicines Agency has accepted its application to expand the use of ‘Nucala’, or ...

GSK (GSK) plc announced that the European Medicines Agency has accepted for review its application to expand the use of Nucala, a monoclonal ...